Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

32.52
-1.7300-5.05%
Post-market: 32.19-0.3300-1.01%19:57 EDT
Volume:2.25M
Turnover:73.93M
Market Cap:3.76B
PE:-10.19
High:34.25
Open:33.99
Low:32.30
Close:34.25
52wk High:43.15
52wk Low:18.92
Shares:115.55M
Float Shares:110.00M
Volume Ratio:0.90
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1920
EPS(LYR):-3.1920
ROE:-47.34%
ROA:-30.27%
PB:5.88
PE(LYR):-10.19

Loading ...

Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly

Tiger Newspress
·
Dec 10, 2025

Top Calls on Wall Street: Nvidia, Apple, Tesla, Micron, Viking, Netflix, Hims, Delta & More

Tiger Newspress
·
Dec 09, 2025

Viking Therapeutics Showcases Advancements in Obesity and Metabolic Disease Drug Pipeline

Reuters
·
Dec 09, 2025

BUZZ-Structure Therapeutics down ahead of weight-loss drug data

Reuters
·
Dec 08, 2025

What's Up With The Jump In Viking Therapeutics Stock?

Benzinga_recent_news
·
Dec 05, 2025

Viking Therapeutics to Join Piper Sandler Healthcare Conference

Reuters
·
Nov 26, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Nov 25, 2025

3 Weight-Loss Drug Stocks To Consider For 2026

Benzinga_recent_news
·
Nov 22, 2025

Viking Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Nov 21, 2025

Strong Enrollment and Promising Strategy Propel Viking Therapeutics to ‘Buy’ Rating

TIPRANKS
·
Nov 20, 2025

Promising Potential of Viking Therapeutics’ VK2735 Justifies Buy Rating

TIPRANKS
·
Nov 19, 2025

Viking Therapeutics completes patient enrollment in VANQUISH-1 clinical trial

TIPRANKS
·
Nov 19, 2025

Viking Therapeutics Completes Enrollment in Phase 3 Obesity Drug Trial

Reuters
·
Nov 19, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 3 Vanquish-1 Trial of Vk2735

THOMSON REUTERS
·
Nov 19, 2025

A Fresh Look at Viking Therapeutics (VKTX) Valuation After Recent Share Price Momentum

Simply Wall St.
·
Nov 15, 2025

Viking Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Nov 12, 2025

Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?

TIPRANKS
·
Nov 11, 2025

Viking Therapeutics (VKTX): Evaluating Valuation After New Obesity Drug Data Spurs Fresh Interest

Simply Wall St.
·
Nov 08, 2025

Viking Therapeutics’ VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

TIPRANKS
·
Nov 08, 2025

Promising Potential of Viking Therapeutics’ VK2735: A Buy Rating Justified by Efficacy in Weight Loss and Metabolic Health

TIPRANKS
·
Nov 07, 2025